Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 0.50 |
| ▸ | HTR1D | P28221 | 15/20 | 0.50 |
| ▸ | HTR1B | P28222 | 15/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429685 | 0.87 | HTR1A (0.66) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL429170 | 0.84 | HTR1A (0.46) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL430518 | 0.81 | HTR1A (0.50) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL428223 | 0.77 | HTR1A (0.68) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL10211919 | 0.73 | HTR1A (0.59) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL10212298 | 0.72 | HTR1A (0.66) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL428465 | 0.72 | HTR1A (0.67) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL428103 | 0.72 | HTR1A (0.66) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL428424 | 0.71 | CYP2C9 (0.66) | HTR1AHTR1DHTR1BSLC6A4KCNH2 | |
| SCHEMBL430976 | 0.68 | HTR1A (0.46) | HTR1AHTR1DHTR1BSLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | BENTLEY JONATHAN (IT) | 2012-01-26 | — | — | US | disclosed |
| EP-1786822-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024517-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022056-A1 | FUSED TRICYCLIC DERIVATIVES FOR THE TREATMENT OF PSYCHOTIC DISORDERS | GABBR1, GABRQ, GABRE | HTR1A 7/4885HTR1D 11/4885HTR1B 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.